Nuo Therapeutics, Inc.
AURX
$1.24
$0.010.78%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 177.74% | 178.19% | 91.94% | 106.48% | 100.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 177.74% | 178.19% | 91.94% | 106.48% | 100.46% |
| Cost of Revenue | 372.80% | 304.68% | 144.10% | 139.13% | 108.70% |
| Gross Profit | 123.14% | 131.29% | 80.66% | 97.50% | 98.26% |
| SG&A Expenses | 35.19% | 37.47% | 41.78% | 24.10% | 16.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.68% | 65.79% | 49.12% | 30.27% | 20.61% |
| Operating Income | 7.93% | 6.46% | -20.30% | -5.06% | 3.51% |
| Income Before Tax | -16.47% | 6.97% | -20.29% | -5.26% | 23.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.47% | 6.97% | -20.29% | -5.26% | 23.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.47% | 6.97% | -20.29% | -5.26% | 23.96% |
| EBIT | 7.93% | 6.46% | -20.30% | -5.06% | 3.51% |
| EBITDA | 10.09% | 9.84% | -16.87% | -3.44% | 4.72% |
| EPS Basic | -14.29% | 11.02% | -14.88% | 0.63% | 31.37% |
| Normalized Basic EPS | 10.71% | 10.13% | -14.47% | 0.00% | 12.50% |
| EPS Diluted | -14.29% | 11.02% | -14.88% | 0.63% | 31.37% |
| Normalized Diluted EPS | 10.71% | 10.13% | -14.47% | 0.00% | 12.50% |
| Average Basic Shares Outstanding | 1.88% | 4.22% | 4.85% | 5.82% | 10.83% |
| Average Diluted Shares Outstanding | 1.88% | 4.22% | 4.85% | 5.82% | 10.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |